Recent news by 
PHO:
Randomized phase 3 study in Denmark demonstrates significant advantage in Bladder Cancer for Hexvix/Cysview blue light cystoscopy over standard white light variant:
https://photocure.com/news/photocurefirst-trial-demonstrating-reduced-recurrence-after-flexible-blue-light-cystoscopy-with-hexvix-in-surveillance/
At Q3 2019 Photocure reported continued record growth in the US as well as upfront payments from Chinese partner Asieris:
https://photocure.com/news/photocure-asa-results-for-the-third-quarter-of-2019/
Further improvements for US reimbursements for Cysview from january 2020:
https://photocure.com/news/photocure-cysview-reimbursement-further-improved-from-january-2020/
Technical analysis:
Technical indicators sliding into high momentum and near overbought values at this price level, so any entry should be done with clear considerations of short term risks.
PHO:Randomized phase 3 study in Denmark demonstrates significant advantage in Bladder Cancer for Hexvix/Cysview blue light cystoscopy over standard white light variant:
https://photocure.com/news/photocurefirst-trial-demonstrating-reduced-recurrence-after-flexible-blue-light-cystoscopy-with-hexvix-in-surveillance/
At Q3 2019 Photocure reported continued record growth in the US as well as upfront payments from Chinese partner Asieris:
https://photocure.com/news/photocure-asa-results-for-the-third-quarter-of-2019/
Further improvements for US reimbursements for Cysview from january 2020:
https://photocure.com/news/photocure-cysview-reimbursement-further-improved-from-january-2020/
Technical analysis:
Technical indicators sliding into high momentum and near overbought values at this price level, so any entry should be done with clear considerations of short term risks.
Related publications
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Related publications
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.